Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow An erratum has been published
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (126)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Boye, J.
Right arrow Articles by Engert, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boye, J.
Right arrow Articles by Engert, A.
Related Collections
Right arrow 2003 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:520-535, 2003
© 2003 European Society for Medical Oncology

Review Article

An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab

J. Boye, T. Elter and A. Engert+

Clinic I of Internal Medicine, University Hospital of Cologne, Cologne, Germany

Received 1 July 2002; revised 18 October 2002; accepted 20 November 2002

Abstract

The chimeric anti-CD20 monoclonal antibody rituximab has become part of the standard therapy for patients with non-Hodgkin’s lymphoma (NHL). To date, more than 300 000 patients have been treated with rituximab worldwide, including patients with indolent and aggressive NHL, Hodgkin’s disease and other B-cell malignancies. Combination of rituximab with cytotoxic agents or cytokines has been explored in a number of different studies. Rituximab is now also approved for patients with diffuse large B-cell lymphoma when combined with standard CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone). The monoclonal antibody is generally well tolerated. Most adverse events are infusion-associated, including chills, fever and rigor related to the release of cytokines.

Key words: chronic lymphocytic leukemia, clinical studies, Hodgkin’s disease, non-Hodgkin’s lymphoma, rituximab


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 LupusHome page
R Abdwani and R Mani
Anti-CD20 monoclonal antibody in acute life threatening haemolytic anaemia complicating childhood onset SLE
Lupus, April 1, 2009; 18(5): 460 - 464.
[Abstract] [PDF]

Home page
 Ann OncolHome page
A. Gondos, F. Bray, T. Hakulinen, H. Brenner, and the EUNICE Survival Working Group
Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis
Ann. Onc., March 1, 2009; 20(3): 564 - 573.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Franchini and G. Lippi
Acquired factor VIII inhibitors
Blood, July 15, 2008; 112(2): 250 - 255.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
J Yeung and H Chang
Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma
J. Clin. Pathol., July 1, 2008; 61(7): 832 - 836.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Du, H. Wang, C. Zhong, B. Peng, M. Zhang, B. Li, S. Huo, Y. Guo, and J. Ding
Structural Basis for Recognition of CD20 by Therapeutic Antibody Rituximab
J. Biol. Chem., May 18, 2007; 282(20): 15073 - 15080.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. Cittera, M. Leidi, C. Buracchi, F. Pasqualini, S. Sozzani, A. Vecchi, J. D. Waterfield, M. Introna, and J. Golay
The CCL3 Family of Chemokines and Innate Immunity Cooperate In Vivo in the Eradication of an Established Lymphoma Xenograft by Rituximab
J. Immunol., May 15, 2007; 178(10): 6616 - 6623.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
H. Schulz, J. F. Bohlius, S. Trelle, N. Skoetz, M. Reiser, T. Kober, G. Schwarzer, M. Herold, M. Dreyling, M. Hallek, et al.
Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis
J Natl Cancer Inst, May 2, 2007; 99(9): 706 - 714.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. El Fassi, C. H. Nielsen, S. J. Bonnema, H. C. Hasselbalch, and L. Hegedus
B Lymphocyte Depletion with the Monoclonal Antibody Rituximab in Graves' Disease: A Controlled Pilot Study
J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1769 - 1772.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Charalambous, M. Oks, G. Nchinda, S. Yamazaki, and R. M. Steinman
Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin
J. Immunol., December 15, 2006; 177(12): 8410 - 8421.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Jeha, F. Behm, D. Pei, J. T. Sandlund, R. C. Ribeiro, B. I. Razzouk, J. E. Rubnitz, N. Hijiya, S. C. Howard, C. Cheng, et al.
Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia
Blood, November 15, 2006; 108(10): 3302 - 3304.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
S. Perez-Gala, Y. Delgado-Jimenez, R. Goiriz, J. Fraga, A. Garcia-Diez, and J. Fernandez-Herrera
Cytokine-release syndrome related to rituximab limited to lesions and excision scars of lesions of primary cutaneous lymphoma.
Arch Dermatol, November 1, 2006; 142(11): 1516 - 1517.
[Full Text] [PDF]

Home page
 LupusHome page
T Kotani, T Takeuchi, Y Kawasaki, S Hirano, Y Tabushi, M Kagitani, S Makino, and T Hanafusa
Successful treatment of cold agglutinin disease with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus
Lupus, October 1, 2006; 15(10): 683 - 685.
[Abstract] [PDF]

Home page
 Eur J EndocrinolHome page
D. El Fassi, C. H Nielsen, H. C Hasselbalch, and L. Hegedus
The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option.
Eur. J. Endocrinol., May 1, 2006; 154(5): 623 - 632.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. C. Cooper, R. M. Karp, E. J. Clark, N. R. Taghizadeh, J. G. Hoyt, M. T. Labenski, M. J. Murray, G. Hannig, W. F. Westlin, and C. D. Thompson
A Novel Methionine Aminopeptidase-2 Inhibitor, PPI-2458, Inhibits Non-Hodgkin's Lymphoma Cell Proliferation In vitro and In vivo
Clin. Cancer Res., April 15, 2006; 12(8): 2583 - 2590.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
F. Fakhouri, B. Deroure, and A. Hummel
A new treatment for TTP?
Nephrol. Dial. Transplant., March 1, 2006; 21(3): 577 - 579.
[Full Text] [PDF]

Home page
 BloodHome page
F. Perosa, E. Favoino, M. A. Caragnano, and F. Dammacco
Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor
Blood, February 1, 2006; 107(3): 1070 - 1077.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. F. DiJoseph, M. M. Dougher, L. B. Kalyandrug, D. C. Armellino, E. R. Boghaert, P. R. Hamann, J. K. Moran, and N. K. Damle
Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma
Clin. Cancer Res., January 1, 2006; 12(1): 242 - 249.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. Fakhouri, J.-P. Vernant, A. Veyradier, M. Wolf, G. Kaplanski, R. Binaut, M. Rieger, F. Scheiflinger, P. Poullin, B. Deroure, et al.
Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases
Blood, September 15, 2005; 106(6): 1932 - 1937.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. N. Gordan, W. B. Grow, A. Pusateri, V. Douglas, N. P. Mendenhall, and J. W. Lynch
Phase II Trial of Individualized Rituximab Dosing for Patients With CD20-Positive Lymphoproliferative Disorders
J. Clin. Oncol., February 20, 2005; 23(6): 1096 - 1102.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. F. DiJoseph, M. E. Goad, M. M. Dougher, E. R. Boghaert, A. Kunz, P. R. Hamann, and N. K. Damle
Potent and Specific Antitumor Efficacy of CMC-544, a CD22-Targeted Immunoconjugate of Calicheamicin, against Systemically Disseminated B-Cell Lymphoma
Clin. Cancer Res., December 15, 2004; 10(24): 8620 - 8629.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Th. Went, S. Dirnhofer, M. Bundi, M. Mirlacher, P. Schraml, S. Mangialaio, S. Dimitrijevic, J. Kononen, A. Lugli, R. Simon, et al.
Prevalence of KIT Expression in Human Tumors
J. Clin. Oncol., November 15, 2004; 22(22): 4514 - 4522.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. S. Cragg, M. B. Bayne, A. L. Tutt, R. R. French, S. Beers, M. J. Glennie, and T. M. Illidge
A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells
Blood, October 15, 2004; 104(8): 2540 - 2542.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
L. Sellin, C. Friedl, G. Klein, R. Waldherr, L. C. Rump, and S. M. Weiner
Acute renal failure due to a malignant lymphoma infiltration uncovered by renal biopsy
Nephrol. Dial. Transplant., October 1, 2004; 19(10): 2657 - 2660.
[Full Text] [PDF]

Home page
 Ann OncolHome page
S. Wohrer, A. Puspok, J. Drach, M. Hejna, A. Chott, and M. Raderer
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma
Ann. Onc., July 1, 2004; 15(7): 1086 - 1090.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
C. Morath, M. Mueller, H. Goldschmidt, V. Schwenger, G. Opelz, and M. Zeier
Malignancy in Renal Transplantation
J. Am. Soc. Nephrol., June 1, 2004; 15(6): 1582 - 1588.
[Full Text] [PDF]

Home page
 JCOHome page
M. J.S. Dyer
Bioweapons of Tumor Mass Destruction?
J. Clin. Oncol., August 15, 2003; 21(16): 3011 - 3012.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.